Foghorn Therapeutics to Present at Four Conferences in May.
ByAinvest
Thursday, May 22, 2025 7:06 am ET1min read
CWEN--
The Evercore Biotech Diamonds in the Rough Virtual Event will feature a fireside chat with Adrian Gottschalk on May 27, 2025, at 2:00 p.m. EDT [1]. The TD Cowen’s 6th Annual Oncology Innovation Summit will also host a fireside chat with Gottschalk on May 28, 2025, at 1:30 p.m. EDT. The Jefferies Global Healthcare Conference 2025, taking place in New York on June 5, 2025, at 3:45 p.m. EDT, will include a presentation by Gottschalk. Additionally, the Goldman Sachs 46th Annual Global Healthcare Conference 2025, scheduled for June 11, 2025, at 10:00 a.m. EDT in Miami, will feature a presentation by Gottschalk.
Foghorn Therapeutics focuses on oncology, leveraging its proprietary Gene Traffic Control® platform to develop a broad pipeline of medicines targeting genetically determined dependencies within the chromatin regulatory system. The company aims to transform the lives of people suffering from a wide spectrum of diseases.
For more information on Foghorn Therapeutics and its upcoming events, please visit their website at www.foghorntx.com [2].
References:
[1] https://www.marketscreener.com/quote/stock/FOGHORN-THERAPEUTICS-INC-114282635/news/Foghorn-Therapeutics-to-Participate-in-Four-Upcoming-Investor-Conferences-50037145/
[2] https://www.foghorntx.com
FHTX--
TD--
TOI--
Foghorn Therapeutics, a clinical-stage biotech company, announced that management will participate in various upcoming conferences. These include the Evercore Biotech Diamonds in the Rough Virtual Event, TD Cowen's 6th Annual Oncology Innovation Summit, Jefferies Global Healthcare Conference 2025, and Goldman Sachs 46th Annual Global Healthcare Conference 2025. The company's focus is on oncology, with the potential to transform lives through its Gene Traffic Control platform and broad pipeline.
Cambridge, Mass., May 22, 2025 (GLOBE NEWSWIRE) — Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company specializing in gene expression correction, has announced its participation in several upcoming investor conferences. The company's management, led by President and CEO Adrian Gottschalk, will present at the Evercore Biotech Diamonds in the Rough Virtual Event, TD Cowen’s 6th Annual Oncology Innovation Summit, Jefferies Global Healthcare Conference 2025, and Goldman Sachs 46th Annual Global Healthcare Conference 2025.The Evercore Biotech Diamonds in the Rough Virtual Event will feature a fireside chat with Adrian Gottschalk on May 27, 2025, at 2:00 p.m. EDT [1]. The TD Cowen’s 6th Annual Oncology Innovation Summit will also host a fireside chat with Gottschalk on May 28, 2025, at 1:30 p.m. EDT. The Jefferies Global Healthcare Conference 2025, taking place in New York on June 5, 2025, at 3:45 p.m. EDT, will include a presentation by Gottschalk. Additionally, the Goldman Sachs 46th Annual Global Healthcare Conference 2025, scheduled for June 11, 2025, at 10:00 a.m. EDT in Miami, will feature a presentation by Gottschalk.
Foghorn Therapeutics focuses on oncology, leveraging its proprietary Gene Traffic Control® platform to develop a broad pipeline of medicines targeting genetically determined dependencies within the chromatin regulatory system. The company aims to transform the lives of people suffering from a wide spectrum of diseases.
For more information on Foghorn Therapeutics and its upcoming events, please visit their website at www.foghorntx.com [2].
References:
[1] https://www.marketscreener.com/quote/stock/FOGHORN-THERAPEUTICS-INC-114282635/news/Foghorn-Therapeutics-to-Participate-in-Four-Upcoming-Investor-Conferences-50037145/
[2] https://www.foghorntx.com
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet